Barry Singer from Missouri Baptist Medical Center: Looking at Long Term Results of Fingolimod

Video

In six years since fingolimod was approved for the treatment of relapsing remitting multiple sclerosis a considerable amount of data has been collected about the oral medication.

In 6 years since fingolimod was approved for the treatment of relapsing remitting multiple sclerosis a considerable amount of data has been collected about the oral medication.

Barry A. Singer, MD, from Missouri Baptist Medical Center discussed the results of the latest research on the medication during the annual ECTRIMS conference in London. Singer said the results in real world practice have proven to be similar to what was seen during clinical trials. This includes both efficacy and safety results. Singer also discussed why a small number of patients on the medication have developed progressive multifocal leukoencephalopathy and what has been learned about that condition in recent years as well.

Recent Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.